Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Inclusion Criteria: Standard: 1. Male or female subjects, age 18 years or greater; and 2. Diagnosed or suspected coronary artery disease with a clinical indication for coronary angiography. Angiographic: 1. Evidence of coronary heart disease 2. Identification of a target native coronary artery for the plaque volume measurement. Exclusion Criteria: Standard: 1. Breast feeding or lactating women, or women who have had a pregnancy (regardless of outcome) within the past 12 months; 2. Previous heart or other organ transplantation; 3. Treatment with any of the following agents within 4 weeks prior to randomization: * Immunosuppressive agents (cyclosporine, azathioprine); * Rifampin; and * Phenytoin, phenobarbital, valproic acid, or other anticonvulsants. 4. Any of the following manifestations of cardiac disease: * Myocardial infarction or unstable angina within 24 hours prior to randomization or clinically unstable; * Clinically significant heart disease; and * Coronary artery bypass surgery within previous 3 months. 5. Stroke (CVA) within previous 3 months; 6. Evidence of severe symptomatic heart failure (NYHA Class III or IV) or known ejection fraction less than 30%; 7. Uncontrolled diabetes mellitus; 8. Uncontrolled hypertension; and 9. Nephrotic syndrome, significant nephropathy, or other significant renal disease. Angiographic: 1. Presence of any lesion with greater than 50% reduction in lumen diameter; or 2. Any lesion with a greater than 50% occlusion in the left main coronary artery; 3. A target vessel, including any of its branches, that has undergone or will be undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI); 4. A target vessel that is itself a bypass graft.